Gifted Molecular Science
- Biotech or pharma, therapeutic R&D
Founded in 2023, Gifted Molecular Science is committed to developing innovative antiviral therapies with a novel mechanism of action to combat COVID-19. With $4.0M from a strategic investor and $1.5M in government research funding, we have launched preclinical studies exploring our cutting-edge therapeutic platform.
Our proprietary druggable-PNA directly targets the RNA genome, offering a breakthrough approach distinct from conventional antivirals. Unlike traditional ASOs, our molecule efficiently crosses the cell membrane and resists enzymatic degradation in vivo, addressing critical challenges of existing therapies.
We are currently advancing our lead candidate, GMS-007, through preclinical development as a potential COVID-19 treatment. This groundbreaking technology also shows promise for treating other RNA viruses, including Dengue, Zika, West Nile, RSV, HMPV, and Influenza.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}